Genetic Clues for Skin Cancer Therapies Alexandria VA

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

David A Spott, MD
(301) 868-7077
9131 Piscataway Rd
Clinton, MD
Business
David A Spott MD
Specialties
Dermatology

Data Provided by:
Charles B Weber, DO
(703) 212-7546
5249 Duke St Ste LL1
Alexandria, VA
Specialties
Dermatology
Gender
Male
Education
Medical School: Des Moines Univ, Coll Osteo Med & Surg, Des Moines Ia 50312
Graduation Year: 1977

Data Provided by:
Thomas Larry Smith, MD
(703) 212-7546
5249 Duke St Ste LL1
Alexandria, VA
Specialties
Dermatology
Gender
Male
Education
Medical School: Univ Of Ms Sch Of Med, Jackson Ms 39216
Graduation Year: 1968

Data Provided by:
Yvette Efua Appiah, MD
(703) 822-0222
6355 Walker Ln Ste 311
Alexandria, VA
Specialties
Dermatology
Gender
Female
Education
Medical School: Univ Of Chicago, Pritzker Sch Of Med, Chicago Il 60637
Graduation Year: 1997

Data Provided by:
Dr.Charles Weber
(703) 212-7546
5249 Duke Street #205
Alexandria, VA
Gender
M
Education
Medical School: Des Moines Univ, Coll Osteo Med & Surg
Year of Graduation: 1977
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Kelly Jo Hunt
(703) 751-2616
5249 Duke St Ste 5
Alexandria, VA
Specialty
Dermatology

Data Provided by:
Bruce David Glassman, MD
(703) 370-0073
4660 Kenmore Ave
Alexandria, VA
Specialties
Dermatology
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1988

Data Provided by:
Alan L Sampson
(703) 751-2616
5249 Duke St Ste 5
Alexandria, VA
Specialty
Dermatology

Data Provided by:
Harold John Berman, MD
(703) 370-0073
4660 Kenmore Ave Ste 1000
Alexandria, VA
Specialties
Dermatology
Gender
Male
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1953
Hospital
Hospital: Inova Alexandria Hospital, Alexandria, Va
Group Practice: Capital Dermatology

Data Provided by:
Simone A McKitty
(703) 370-0073
4660 Kenmore Ave Ste 1000
Alexandria, VA
Specialty
Dermatology

Data Provided by:
Data Provided by:

Genetic Clues for Skin Cancer Therapies

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com